Olema Pharmaceuticals, Inc. (NASDAQ:OLMA – Get Free Report) Director Cyrus Harmon sold 25,000 shares of the stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $12.41, for a total value of $310,250.00. Following the completion of the transaction, the director now owns 846,283 shares in the company, valued at $10,502,372.03. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
Cyrus Harmon also recently made the following trade(s):
- On Wednesday, January 31st, Cyrus Harmon sold 25,000 shares of Olema Pharmaceuticals stock. The shares were sold at an average price of $12.23, for a total transaction of $305,750.00.
Olema Pharmaceuticals Trading Down 5.0 %
OLMA opened at $13.83 on Wednesday. Olema Pharmaceuticals, Inc. has a 12 month low of $3.00 and a 12 month high of $17.79. The company has a market cap of $762.03 million, a PE ratio of -5.96 and a beta of 2.13. The company has a 50 day moving average of $13.34 and a 200 day moving average of $12.96.
Wall Street Analyst Weigh In
Read Our Latest Stock Report on OLMA
Hedge Funds Weigh In On Olema Pharmaceuticals
Large investors have recently made changes to their positions in the stock. Perceptive Advisors LLC bought a new position in shares of Olema Pharmaceuticals in the fourth quarter valued at approximately $7,574,000. Virtus ETF Advisers LLC purchased a new position in shares of Olema Pharmaceuticals during the 4th quarter valued at about $105,000. Legal & General Group Plc boosted its stake in shares of Olema Pharmaceuticals by 910.8% in the 4th quarter. Legal & General Group Plc now owns 24,533 shares of the company’s stock valued at $344,000 after purchasing an additional 22,106 shares in the last quarter. Barclays PLC raised its position in Olema Pharmaceuticals by 831.8% in the 4th quarter. Barclays PLC now owns 43,396 shares of the company’s stock worth $609,000 after purchasing an additional 38,739 shares during the period. Finally, Vanguard Group Inc. lifted its stake in Olema Pharmaceuticals by 58.2% in the fourth quarter. Vanguard Group Inc. now owns 2,705,895 shares of the company’s stock worth $37,964,000 after purchasing an additional 995,588 shares during the last quarter. 88.00% of the stock is owned by institutional investors.
Olema Pharmaceuticals Company Profile
Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1b/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer.
See Also
- Five stocks we like better than Olema Pharmaceuticals
- What is an Earnings Surprise?
- Boeing Wants to Buy Its Supplier on Recent Drama, Here’s Why
- The Most Important Warren Buffett Stock for Investors: His Own
- Cava Group Serves Up 60% Gain Amid Strong Post-IPO Buying
- Basic Materials Stocks Investing
- Gitlab Goes on Sale: The AI Bubble Burst for This Stock
Receive News & Ratings for Olema Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Olema Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.